News
Recruitment for the FAIR PARK II study is now closed: The last patient has been enrolled on December 5th 2019
The FAIR-PARK II 6h annual meeting was held virtually on 22nd April 2021
The FAIR-PARK II 5th annual meeting was held in Paris, France on 26th June 2019.
The FAIR-PARK II 4th annual meeting was held in Lisbon, Portugal on 15th and 16th June 2018.
The FAIR-PARK II 3rd annual meeting was held in Amsterdam, Netherlands on 26th and 27th June 2017.
The FAIR-PARK II 2nd annual meeting was held in Berlin, Germany on 23-24 June 2016.
The FAIR-PARK II kick-off meeting was held in Lille, France on 4-5 May 2015.
Recruitment for the FAIR PARK II study is now open: The first patient has been enrolled in Lille's hospital on February 9th 2016
The final list of European expert centres for the clinical trial is available since October 2015.
The final version of the protocol, as released by competent authorities and ethic national committees is available since january 2016
Patient Recruitment Countdown
16th December 2019
Patients to be recruited
0
Patients recruited
372
The recruitment is now closed
Professor Joaquim Ferreira is a Professor of Neurology and Clinical Pharmacology at the Faculty of Medicine, University of Lisbon and Head of the Laboratory of Clinical Pharmacology and Therapeutics. He completed his medical degree and PhD in Neurology at the University of Lisbon. He became interested in movement disorders during his medical degree and later undertook a Clinical Pharmacology fellowship with Prof Olivier Rascol in Toulouse, France. He is currently the chair of the European Section of The International Parkinson and Movement Disorder Society. His major research interests are neuropharmacology, Parkinson’s disease, dystonia and Huntington’s disease.
Jacques Demotes-Mainard (MD, PhD, MBA) is Neurologist and Professor of Cell Biology. Coordinator since 2004 of four FP6 and FP7 ECRIN projects, and currently Director-General of ECRIN-ERIC, a not-for-profit research infrastructure supporting multinational clinical trials in Europe.
Dr Gian Luca Forni is a hematologist with an expertise in iron chelation therapies indicated for systemic siderosis. He has experience with the safety profile of deferiprone and notably for the neutropenia and agranulocytosis. He collaborated on the first pilot trial of chelation with deferiprone in “Neurodegeneration with Brain Iron Accumulation”.
Holm Graessner, PhD, MBA, is managing director of the Rare Disease Centre Tübingen and head of the research management unit of the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. He has profound experience in project management of collaborative projects such as the FP6 and FP7 EU projects EUROSCA, MEFOPA, RATstream, SENSE-PARK, TreatPolyQ, MultISyn and NeurOmics.
Prof. Tolosa is a neurologist by the American Board of Neurology and Psychiatry. He is a fellow of the American Academy of Neurology, the American Neurological Association and the Royal College of Physicians, and a founding member of the Movement Disorder Society (MDS). He’s currently a Senior Consultant at the Department of Neurology at the Hospital Clinic Universitari in Barcelona
Prof. Tolosa’s research interests have centered on movement disorders and particularly in issues related to experimental therapeutics, etiology and pathophysiology of various parkinsonisms. His team has been among the first in Europe to evaluate efficacy of novel surgical strategies for Parkinson’s disease such as subthalamic nucleus stimulation and its impact upon patients cognition and quality of life. In addition, during the last years, he has dedicated his investigations to the study of the asymptomatic individuals carrying PD-causative mutations in the LRRK2 gene.
Form 1
Form 2
Form 3
Form 4
FAIR PARK II
Conservative iron chelation as a disease modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomised clinical trial of deferiprone
Latest News Articles
Navigation
Contact Us
People
Scientific Coordinator: Prof David Devos
Project Manager (CHRUL): Pauline Guyon [email protected]
Senior Project Manager (IT): Delphine Smagghe [email protected]
Project Manager (IT): Stephanie Le Naour [email protected]
Addresses
Centre Hospitalier Regional et Universitaire de Lille (CHRUL), 2 avenue Oscar Lambret - 59037 Lille Cedex
Inserm-Transfert (IT), 7 rue de Watt - 75013 Paris, France
Lille CHRUL
Paris Inserm Transfert
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633190.
© FAIRPARK II 2015